Clinical trials
Idiopathic Pulmonary Fibrosis trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
64 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2012 | 2 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 6 |
| 2021 | 10 |
| 2022 | 4 |
| 2023 | 8 |
| 2024 | 8 |
| 2025 | 10 |
| 2026 | 10 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 27 |
| Recruiting | 11 |
| Not yet recruiting | 9 |
| Terminated | 6 |
| Unknown status | 6 |
| Active, not recruiting | 4 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Boehringer Ingelheim | 6 |
| Sunshine Lake Pharma Co., Ltd. | 5 |
| Henan University of Traditional Chinese Medicine | 4 |
| Bristol-Myers Squibb | 3 |
| Guangdong Hengrui Pharmaceutical Co., Ltd | 3 |
| Guangzhou JOYO Pharma Co., Ltd | 3 |
| Overseas Pharmaceuticals, Ltd. | 3 |
| Regend Therapeutics | 3 |
| Hoffmann-La Roche | 2 |
| InSilico Medicine Hong Kong Limited | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Idiopathic Pulmonary Fibrosis | 64 |
| Pulmonary Fibrosis | 11 |
| Lung Diseases, Interstitial | 6 |
| Idiopathic Interstitial Pneumonias | 4 |
| Lung Diseases | 4 |
| Respiratory Tract Diseases | 4 |
| Bronchiectasis | 1 |
| Fibrosis | 1 |
| Hypertension, Pulmonary | 1 |
| Pathologic Processes | 1 |
Trials
Showing 51 to 64 of 64. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.